Zacks Investment Research
29 Jul 2026, 22:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Recursion Pharmaceuticals (RXRX) consensus revenue estimates for the upcoming quarter are down 37.64% year-over-year to $11.99 million. — A significant decline in projected quarterly revenue typically signals weakening business momentum or loss of market share.
-0.40Recursion Pharmaceuticals is projected to report earnings per share of -$0.25, a 39.02% increase from the prior year's loss. — While still negative, a narrowing of losses suggests a positive trend in cost management or operational efficiency.
+0.20Recursion Pharmaceuticals currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating indicates a neutral outlook with no immediate strong buy or sell signal for investors.
+0.00Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company's stock price is lagging the S&P 500, has dropped over 16% in a month, and is projecting a significant year-over-year revenue decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
